Evaluate the role of anti-VEGF immunotherapy in a mouse model of cognitive function and brain plasticity.
Coordinator: Castel, H
Title: Evaluation of VEGF immunoneutralisation on mouse cognitive function and brain plasticity.
Background: Bevacizumab is a humanised anti-VEGF monoclonal antibody approved by the Food and Dug Administration in 2009 for colorectal, breast and lung cancer as well as glioblastomas. Cases of leucoencephalopathys have been described during bevacizumab treatment and during two clinical trials conducted in parallel, one in the United States (RTOG 0825) and the other in Europe (AVAGlio). These studies were presented in 2013 to the French society of Neuro-oncology and demonstrated contradictory results regarding bevacizumab’s role. Subsequently, targeted anti-angiogenic therapy may cause memory impairment in treated patients, but they may also cause fatigue.
Study methodology: Behavioural tests in C57B/L6 mice and neurobiological analyses on brain samples. Administration of targeted therapy via intraperitoneal injection. Plasma and intracerebral levels of VEGF.
Current study status: Finalisation phase.
Collaboration: Centre F. Baclesse and Genentech US (Roche)
Sponsor: Inserm, Région Haute-Normandie and Cancéropôle Nord-Ouest